1. Home
  2. CUE vs JVSA Comparison

CUE vs JVSA Comparison

Compare CUE & JVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • JVSA
  • Stock Information
  • Founded
  • CUE 2014
  • JVSA 2021
  • Country
  • CUE United States
  • JVSA Hong Kong
  • Employees
  • CUE N/A
  • JVSA N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • JVSA
  • Sector
  • CUE Health Care
  • JVSA
  • Exchange
  • CUE Nasdaq
  • JVSA NYSE
  • Market Cap
  • CUE 94.4M
  • JVSA 80.7M
  • IPO Year
  • CUE 2018
  • JVSA 2024
  • Fundamental
  • Price
  • CUE $1.38
  • JVSA $10.58
  • Analyst Decision
  • CUE Strong Buy
  • JVSA
  • Analyst Count
  • CUE 5
  • JVSA 0
  • Target Price
  • CUE $5.00
  • JVSA N/A
  • AVG Volume (30 Days)
  • CUE 245.9K
  • JVSA 28.5K
  • Earning Date
  • CUE 03-10-2025
  • JVSA 01-01-0001
  • Dividend Yield
  • CUE N/A
  • JVSA N/A
  • EPS Growth
  • CUE N/A
  • JVSA N/A
  • EPS
  • CUE N/A
  • JVSA 0.24
  • Revenue
  • CUE $9,532,000.00
  • JVSA N/A
  • Revenue This Year
  • CUE $73.11
  • JVSA N/A
  • Revenue Next Year
  • CUE $11.02
  • JVSA N/A
  • P/E Ratio
  • CUE N/A
  • JVSA $43.72
  • Revenue Growth
  • CUE 149.53
  • JVSA N/A
  • 52 Week Low
  • CUE $0.45
  • JVSA $10.02
  • 52 Week High
  • CUE $2.37
  • JVSA $10.64
  • Technical
  • Relative Strength Index (RSI)
  • CUE 52.01
  • JVSA N/A
  • Support Level
  • CUE $1.22
  • JVSA N/A
  • Resistance Level
  • CUE $1.50
  • JVSA N/A
  • Average True Range (ATR)
  • CUE 0.12
  • JVSA 0.00
  • MACD
  • CUE -0.00
  • JVSA 0.00
  • Stochastic Oscillator
  • CUE 55.38
  • JVSA 0.00

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About JVSA JVSPAC ACQUISITION CORP

JVSPAC Acquisition Corp is blank check company.

Share on Social Networks: